MediPharm Labs (TSX: LABS), announced today that it’s Australian subsidiary MediPharm Labs Inc. has filed a statement of claim in the Ontario Superior Court of Justice against an (unknown) licensed producer.
The claim addresses the payment of outstanding amounts ($9.8 million), pursuant to a private label cannabis oil agreement. This was in reference to MediPharm Lab’s February 11, 2019 press release.
About MediPharm Labs
Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical quality cannabis oil and concentrates and advanced derivative products utilizing a Good Manufacturing Practices certified facility and ISO standard built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm Labs formulates, sensory-tests, processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, MediPharm Labs has completed commercial exports to Australia and is nearing commercialization of its Australian extraction facility. MediPharm Labs Australia was established in 2017.